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ABSTRACT
OBJECTIVE: To assess the value of extended volume irradiation with anastomotic coverage in high
risk resected esophageal cancer patients.

METHOD:

A retrospective study was undertaken at LRCC from 1989-1999 for high risk resected

esophageal cancer patients.

Adjuvant treatments consisted of 4 cycles of chemotherapy

(epirubicin/fluorouracil/cisplatin or cisplatin/fluorouracil), and local regional irradiation with or without
coverage of the anastomotic site. Radiation dose ranged from 45-60Gy at 1.8-2.0 Gy/fraction given with
initial anterior-posterior/posterior-anterior arrangement with either extended (with anastomotic coverage)
or small (without anastomotic coverage) field followed by oblique fields for boost.

RESULT:

One hundred eighty-eight charts were reviewed. Seventy-two patients were eligible for

post-resection chemoradiation therapy. Three patients had disease progression prior to therapy, and 69
patients were analyzed.

There were 81% T3N1 and 13% T2N1.

Thirty-four patients had margin

involvements (radial 53%; proximal/distal 32%), 65% were adenocarcinoma and 33% were squamous
carcinoma. Median followup was 23.6 months (3.4 - 78.4 months). Two year survival was 50%; 5yr 24%.
Relapse rate was 62.3% and median time to relapse was 20 months. Recurrence locally to anastomosis
or adjacent to anastomosis was 9/43(20.9%) with small field and 2/26(7.7%) with extended field. Of 31
patients with relapse outside anastomosis, 14/20(70%) relapsed locoregional/distal when treated with
small field and 3/11(27%) relapsed locoregional/distal when treated with extended field (p=0.02). There
was no excess treatment interruption or chronic gastrointestinal toxicity with extended field irradiation.

CONCLUSION: There is

significant decrease in locoregional/distal relapse with use of extended

field in high risk resected esophageal cancer patients.
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Introduction
•

surgery has been the standard treatment for localized esophageal cancer (1)

•

anastomotic recurrence of disease after transthoracic esophagectomy can occur, particularly
with histologically involved surgical margins (2)

•

frequency of locoregional recurrence is related to the length of resection margin (3), lymph
node involvement (4), invasion of neighbouring organs (5) and circumferential resection
margin involvement (6)

•

radiation treatment planning and target volume for esophageal cancer patients is
controversial (7). There is no clear consensus as to what constitutes the optimal treatment
volume and the balance between tumor control and normal tissue toxicity for high risk
patients (close or positive microscopic margins and lymph node involvement) after
esophagectomy

•

at LRCC thoracic radiation oncologists have different practice preferences on the inclusion
of the post-surgical anastomotic site within the irradiation volume even if the pathological
margins (proximal and distal) are not involved

•

the present study is to review the results of those high risk patients after esophagectomy
treated with either small (without anastomotic coverage) or extended (with anastomotic
coverage) field of radiation at LRCC during the period of 1989-1999
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Patient & Methods
•

a retrospective chart review was undertaken at London Regional Cancer Centre (LRCC)
from 1989-1999, for high risk resected esophageal cancer patients (T3 disease with nodal
involvement, positive margin and/or with residual disease)

•

adjuvant treatments consisted of 4 cycles of chemotherapy i.e. ECF (epirubicin 50 mg/m2, 5
FU 200 mg/m2 and cisplatin 60 mg/m2) with epirubicin omitted during the concurrent phase
with radiation therapy or 4 cycles of cisplatin (100 mg/m2) and 5 FU (1000 mg/m2)

•

irradiation was given during the 3rd cycle of chemotherapy. Irradiation dose ranged from 4560 Gy at 1.8 - 2.0 Gy/fx given with initial anterior-posterior/posterior-anterior arrangement
with either extended (with anastomotic coverage - field size range 22 x 12 cm - 28 cm x 12 median 24 x 12 cm) or small (without anastomotic coverage - field size range 12 x 10 cm 22 x 12 cm - median 19 x 12 cm) field followed by oblique fields for boost

•

resection margins were covered within the radiation portal if it was close or involved
regardless of whether small or extended field was used

•

megavoltage machine with energy > 6 MV were used

•

statistic was analyzed with chi-square and Log Rank

•

treatment toxicity including chemo/radiation delay, chemotherapy dose reduction GI
symptoms such as esophagitis, diarrhea, bowel obstruction, tracheo esophageal fistula etc.
were analyzed
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Results
Total:

188 patient charts reviewed
72 patients referred to LRCC with high risk features for adjuvant chemoradiation
therapy
3 patients with disease progression while on treatment
69 patients analyzed
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Results
Patient Characteristics:
Age

<

65 yo

41

(59%) range

>

65 yo.

28

(41%)

male

62

(90%)

Female

7

(10%)

T2N1

9

(13%)

T3N1

55

(81%)

T4N0

2

(3%)

T4N1

2

(3%)

Transhiatal

59

(86%)

Transthoracic 10

(14%)

Sex

35-82 yo.

median 60 yo

Pathological
Stage

Surgery

Pathology
Squamous

23

(33%)

Adenocarcinoma

45

(65%)

1

(1%)

Other
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Results
Margin features
34 patients with margin involvement
proximal/distal margins

11/69

(15%)

18/69

(26%)

5/69

(7%)

close/involvement
radial margins
close/involvement
both
Patient With Extended Field
Margin Involvement

20/26 (77%)

9/26 (35%) radical margin
7/26 (27%) proxi/distal margin
4/26 (15%) both

Patient With Small Field
Margin Involvement
9/43

14/43 (33%)

(21%) radical margin

4/43 (10%) proxi/distal margin
1/43 (2%) both
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Results
Treatment
Chemotherapy
Cisp + 5 FU

=

47

(68%)

ECF

=

20

(29%)

Other

=

2

(3%)

Radiation Therapy
Extended Volume (covering anastomosis)
26/69

patients

(37.6%)

Small Volume (without covering anastomosis)
43/69

patients

(62.4%)
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Results
Follow-up:
3.4

-

78.4 months

median

23.6 months

Survival:
Overall 2 years

50%

5 years

24%

Survival curve:
Overall Survival
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Results
Relapse:
Rate

43/69

Median time relapse

(62.3%)
19.9 months

Pattern:
Local Regional

9/43

(20%)

Local Regional Distal

17/43

(40%)

Distal Only

17/43

(40%)
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Results
Relapse sites

Number of Relapse

neck nodes/mass

9

bone

9

abdominal mass

7

liver

6

lung

6

brain

4

skin

2

stomach

2

adrenal

2
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Results
Anastomosis relapse:
of 9 patients with local regional relapse (all not covered anastomosis site)
5 recurred to anastomotic site only
4 recurred adjacent to anastomotic site
∴ anastomotic recurrence rate (without coverage by XRT) 9/43 (20.9%)
∴ anastomotic recurrence rate (with coverage by XRT) 2/26 (7.7%)
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Results
Relapse outside anastomosis
Treatment volume

31 patients

Patient number

Small field

20

Extended field

11

p

=

Local regional distal
relapse
14
3

Distal relapse only
6
8

0.02 chi square
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Results
Effects of Various Factors on Relapse-Free Interval

Factor

Log Rank P-Value

Margin-negative vs. positive

0.66

Resection margin-small field

0.86

vs. extended field
Type of surgery - transhiatal

0.74

vs. transthoracic
ECF Chemo regimen- yes vs.

0.22

no
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Results
Complications:
•

XRT interruption

small field vs extended field

p = 0.26 chi2

•

Chemotherapy delays

small field vs. extended field

p = 0.09 chi2

•

Chemotherapy dose reduction

small field vs. extended field

p = 1.0 chi2

•

Late toxicity (L’Hermites,
trachoesophageal fistula, bowel
obstruction, Liver/Kidney damage,
peripheral neuropathy, weight loss,
chronic diarrhea, etc)

small field vs. extended field

p = 0.70 chi2
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Summary and Conclusion

1.

In our patient population with high risk post-resection relapse rate was 62.3%.

2.

Anastomosis recurrence of 20% if it is not covered with XRT portal.

3.

There is significant decrease in locoregional/distal relapse with use of extended field in
high risk resected esophageal cancer patients.

4.

There is no increase in late toxicity, XRT interruption, and chemotherapy delay when
extended irradiation field is used.

5.

Ongoing phase I/II trial at LRCC to examine the feasibility of extended target volume for
radiation therapy of resected high risk esophageal cancer patients.
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